Neurocrine Biosciences | NBIX - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
AbbVie USD 3.63B 54M 2026-06
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
ALKERMES USD 196.64M 67.96M 2026-06
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Amgen USD 1.72B 134M 2026-06
Biogen USD 709.7M 155.4M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Cytokinetics USD 104.4M 499K 2026-06
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Exelixis USD 147.63M 8.03M 2026-06
Gilead Sciences USD 1.52B 70M 2026-06
Halozyme Therapeutics USD 57M 10.71M 2026-06
Incyte USD 351.73M 23.64M 2026-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Pfizer USD 3.41B 496M 2026-06
Prothena USD 12.67M 5.02M 2026-03
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Repligen USD 76.62M 82K 2026-06
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Teva Pharmaceutical Industries USD 1.03B 34M 2026-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06